Pharmacotherapy for closure of large patent ductus arteriosus in preterm neonates: Fail once, not twice

Stephanie L. Perrier, MD, and Igor E. Konstantinov, MD, PhD, FRACS

A very interesting, thought-provoking, and important article written by Mashally and colleagues is published in this issue of the Journal. They studied a challenging group of preterm infants in whom conventional medical therapy failed to close patent ductus arteriosus (PDA). They aimed to determine whether subsequent acetaminophen administration would effectively close the PDA, thus obviating the need for surgery. Indeed, it appears that such administration of acetaminophen may decrease the need for surgical closure of PDA. It remains unknown, however, whether the same decrease in need for surgery may be achieved by merely waiting longer. In fact, in as many as 40% of low–birth weight premature neonates, the PDA will close spontaneously by postnatal day 8. The rate of spontaneous ductal closure beyond this period is unknown, because most neonatologists would attempt to close PDA medically or surgically by then. If the medical therapy, indomethacin or ibuprofen, fails, most infants would have surgical closure by about 3 or 4 weeks after birth.

Mashally and colleagues have demonstrated that the rate of surgery can be decreased with acetaminophen. At what cost? It appears that prolonged exposure to PDA circulation was associated with about 3-fold increased risk of chronic lung disease. Although not directly comparable, infants who received acetaminophen treatment had significantly longer exposure to PDA circulation than did those infants who received surgical closure (41 days vs 28 days; \( P < .01 \)). Moreover, roughly half of the infants who underwent acetaminophen treatment still required surgical PDA closure. Does a 20% reduction in the need for low-risk surgery justify a prolonged exposure to PDA circulation, with increased risk for subsequent chronic lung disease? How do we define a success or a failure? Should successful medical closure of PDA at cost of a more than 3-fold increase in chronic lung disease be considered a success or a failure of medical management?

In a view of exceptionally low mortality and morbidity related directly to surgical closure of PDA, it might be a mistake to subject the infants to the risks associated with prolonged exposure to a large PDA. It appears that the risks of prolonged exposure to PDA outweigh the exceptionally small risk of surgical PDA ligation.

It might be appropriate to mention a famous quote attributed to Roman statesman Marcus Tullius Cicero (106–43 BC), “Cuiusvis hominis est errare, nullius nisi insipientis in errore perseverare,” which can be translated from Latin as, “Any man can make a mistake; only a fool persists making the same mistake.” The judgment in medicine is often difficult. What is a mistake, and what is not? Intuitively, it appears that if medical therapy fails once, it may not be prudent to persist with yet another medical therapy merely to decrease the need for low-risk surgery, particularly at a cost of significant medical morbidity. Despite the feverish research activity, the question on the optimal time and method of PDA closure remains unanswered. Will there ever be a randomized controlled trial to provide a definitive answer? It is yet to be seen.

References

